ProMIS demonstrated dose-dependent reduction of amyloid-beta oligomers in cerebrospinal fluid following a single dose of PMN310 in Phase 1a testing, with good tolerability and a 27-day CSF half-life supporting longer dosing intervals. A Phase 1b trial enrolling 144 participants is underway, with interim data expected in coming weeks and full results by early 2027.
Key Points
- Dose-dependent oligomer reduction persists 29 days post-dose
- Oligomer-selective mechanism with no monomer or plaque binding
- Phase 1b trial of 144 participants nearing interim readout
Longevity Analysis
Oligomeric amyloid-beta — not plaques — increasingly appears central to cognitive decline and neurodegeneration. A therapeutic targeting specifically oligomers rather than the broader amyloid cascade represents a meaningful refinement in mechanism. The extended CSF half-life and dose-dependent kinetics suggest potential for less frequent dosing schedules, which directly affects adherence and real-world effectiveness. Success in Phase 1b would indicate the approach can achieve sufficient central nervous system exposure in symptomatic populations — a critical distinction from healthy volunteer studies.
Original published by Longevity.Technology.